Publications by authors named "Carina Behr"
Article Synopsis
- Lung cancer screening (LCS) using low-dose CT can be enhanced by also screening for chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), aiming to engage participants from four European countries.
- An online survey targeting smokers aged 50-75 assessed their willingness to partake in this combined screening and identified key participation barriers using analytical hierarchy processing (AHP).
- Results showed a slight increase in willingness to screen with more diseases included, with personal perceived risk being the biggest factor influencing participation, while barriers like missed cases and screening frequency were the most significant issues.
Introduction: Cardiovascular disease (CVD) is the most prominent cause of death worldwide and has a major impact on healthcare budgets. While early detection strategies may reduce the overall CVD burden through earlier treatment, it is unclear which strategies are (most) efficient.
Aim: This systematic review reports on the cost effectiveness of recent early detection strategies for CVD in adult populations at risk.
Background: Chest low-dose computed tomography (LDCT) is a promising technology for population-based screening because it is non-invasive, relatively inexpensive, associated with low radiation and highly sensitive to lung cancer. To improve the cost-effectiveness of lung cancer screening, simultaneous screening for other diseases could be considered. This systematic review was conducted to analyse studies that published evidence on the cost-effectiveness of chest LDCT screening programs for different diseases.
View Article and Find Full Text PDFObjectives: Estimating the maximum acceptable cost (MAC) per screened individual for low-dose computed tomography (LDCT) lung cancer (LC) screening, and determining the effect of additionally screening for chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD), or both on the MAC.
Methods: A model-based early health technology assessment (HTA) was conducted to estimate whether a new intervention could be cost-effective by calculating the MAC at a willingness-to-pay (WTP) of €20k/quality-adjusted life-year (QALY) and €80k/QALY, for a population of current and former smokers, aged 50-75 years in The Netherlands. The MAC was estimated based on incremental QALYs gained from a stage shift assuming screened individuals are detected in earlier disease stages.